Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Nature Communications
|
December 16, 2021
CD137 (4-1BB) costimulation of CD8<sup>+</sup> T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, et al.
Nature Medicine
|
February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.
Nature Communications
|
May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Neil H Segal, Ignacio Melero, Victor Moreno, et al.
The Journal of Clinical Investigation
|
May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Alvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2026
Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab
Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamón, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitors
Thomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Immunity
|
April 15, 2020
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Álvaro Teijeira, Saray Garasa, María Gato, et al.
Neuro-Oncology Advances
|
August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
James R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Cancer Research Communications
|
February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Science Translational Medicine
|
October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Iván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Nature Communications
|
December 16, 2021
CD137 (4-1BB) costimulation of CD8<sup>+</sup> T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, et al.
Nature Medicine
|
February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.
Nature Communications
|
May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Neil H Segal, Ignacio Melero, Victor Moreno, et al.
The Journal of Clinical Investigation
|
May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Alvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2026
Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab
Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamón, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitors
Thomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Immunity
|
April 15, 2020
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Álvaro Teijeira, Saray Garasa, María Gato, et al.
Neuro-Oncology Advances
|
August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
James R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Cancer Research Communications
|
February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Science Translational Medicine
|
October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Iván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Page
of 6